KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $70000.0.

  • Aquestive Therapeutics' Gains from Investment Securities fell 6534.65% to $70000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $793000.0, marking a year-over-year decrease of 2553.99%. This contributed to the annual value of $1.1 million for FY2024, which is 43970.59% up from last year.
  • Aquestive Therapeutics' Gains from Investment Securities amounted to $70000.0 in Q3 2025, which was down 6534.65% from -$803000.0 recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Gains from Investment Securities high stood at $1.5 million for Q1 2025, and its period low was -$803000.0 during Q2 2025.
  • Its 5-year average for Gains from Investment Securities is $128842.1, with a median of $61000.0 in 2022.
  • The largest annual percentage gain for Aquestive Therapeutics' Gains from Investment Securities in the last 5 years was 82142.86% (2024), contrasted with its biggest fall of 160000.0% (2024).
  • Aquestive Therapeutics' Gains from Investment Securities (Quarter) stood at $51000.0 in 2021, then soared by 119.61% to $112000.0 in 2022, then plummeted by 131.25% to -$35000.0 in 2023, then soared by 102.86% to $1000.0 in 2024, then surged by 6900.0% to $70000.0 in 2025.
  • Its Gains from Investment Securities was $70000.0 in Q3 2025, compared to -$803000.0 in Q2 2025 and $1.5 million in Q1 2025.